The FDA has granted a controversial accelerated approval to Biogen’s anti-amyloid antibody aducanumab. Despite a lack of evidence that the therapy improves cognitive outcomes, the FDA approved the antibody based on its ability to lower the level of amyloid plaques in the brain.

Click here to original publication.